Dr. Antoni Ribas is Professor of Medicine, Surgery, and of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), and the current President of the American Association of Cancer Research (AACR). He is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on cancer immunotherapies with immune checkpoint inhibitors and genetically-engineered adoptive cell transfer (ACT) therapies. He is an elected member of the American Society of Clinical Investigation (ASCI), the recipient of the Richard and Hinda Rosenthal Award, the Lloyd J. Old Award in Cancer Immunology, the William B. Coley Award, a National Cancer Institute (NCI) Outstanding Investigator Award, and is a Fellow of the Academy of the AACR.
He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda®), vemurafenib (Zelboraf®), cobimetinib (Cotellic®), dabrafenib (Tafinlar®) and trametinib (Mekinist®).
Dr Ribas received his M.D. degree from the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA.